First‑Line and Adjunctive Therapies for Female Pattern Hair Loss in Postmenopausal Women

First‑Line Topical Therapy

The Endocrine Society guideline states that topical minoxidil 5 % foam applied once daily is the only treatment with high‑level (Level B) evidence for female pattern hair loss and should be initiated before any other modality. 1
A 5 % formulation is superior to a 2 % formulation; once‑daily foam provides efficacy comparable to twice‑daily 2 % solution while improving adherence. 2
Patients should be informed that a transient increase in hair shedding during weeks 2–8 is expected and reflects pharmacologic activity. 2
Continuous therapy for a minimum of 12 months is required before assessing overall response; many women notice improvement only after ≥6 months of use. 2
Common adverse effects of topical minoxidil include scalp pruritus and flaking (more frequent with propylene‑glycol solutions) and facial hypertrichosis, which occurs more often with the 5 % strength than with 2 %. 2

If minoxidil alone is inadequate after 12 months, or if the patient presents with severe hair loss or documented hyperandrogenism, addition of systemic anti‑androgen therapy is recommended. 1
Finasteride 2.5–5 mg daily is the preferred agent for postmenopausal, normoandrogenic women; the 1 mg dose used in men is ineffective in women. Evidence is moderate. 1
Spironolactone 100–200 mg daily (Level B) requires at least 12 months of therapy; 44–74 % of treated women achieve hair regrowth or stabilization, with higher response rates in those who also have hirsutism or acne. 1
Dutasteride 0.15 mg daily has limited (Level D) evidence but may produce superior regrowth compared with finasteride in women younger than 50 years; because of its long half‑life, contraception must be continued for ≥6 months after discontinuation. 2
Flutamide is not recommended because of rare but serious hepatotoxicity despite potential efficacy. 1
Cyproterone acetate has unclear effectiveness (Level C) and is not available in the United States. 1

Low‑dose oral minoxidil (0.625–5 mg daily, typically initiated at 1.25 mg) is increasingly used off‑label when topical minoxidil causes irritation, when diffuse scalp involvement exists, or when patients prefer an oral route. 2
Absolute contraindications include pheochromocytoma, acute myocardial infarction, severe coronary artery disease, heart failure, and hypersensitivity to minoxidil. 2
Precautions requiring cardiology or internal‑medicine consultation are a history of arrhythmia, hypotension (< 90/60 mmHg), or significant renal impairment (including dialysis). 2
Reported adverse effects of oral minoxidil are facial hypertrichosis (~24 %, dose‑dependent), transient shedding (16–22 %), mild peripheral edema (~2 %), and short‑lasting vasodilatory symptoms (dizziness, tachycardia, palpitations) that peak between days 3–7. 3

Prior to therapy, obtain a comprehensive laboratory panel to identify reversible contributors: total testosterone measured by LC/MS, free testosterone (equilibrium dialysis or calculated from SHBG), serum ferritin (target > 70 ng/mL), complete blood count with serum iron, TSH and free T4, 25‑OH vitamin D (replete to ≥ 30 ng/mL), serum zinc, and prolactin. 2

Pitfall: Using topical estradiol cream off‑label for hair loss despite lack of FDA approval and absence of high‑quality efficacy data. Solution: Initiate topical minoxidil 5 % as first‑line therapy. 1
Pitfall: Discontinuing minoxidil before a 12‑month trial because of perceived lack of effect or early shedding. Solution: Counsel patients that early shedding (weeks 2–8) is expected and that a minimum 12‑month duration is required to judge efficacy. 2
Pitfall: Prescribing the 1 mg finasteride dose (approved for men) to postmenopausal women. Solution: Use finasteride 2.5–5 mg daily; the 1 mg dose is ineffective in women. 1
Pitfall: Omitting a comprehensive androgen and metabolic workup before initiating therapy. Solution: Order the full laboratory panel listed above to detect and treat reversible causes of hair loss. 2